METHYLATED PROMOTERS AS BIOMARKERS OF COLON CANCER

• US 20080081333A1
• Filed: 05/25/2007
• Published: 04/03/2008
• Est. Priority Date: 05/26/2006
• Status: Abandoned Application

• Current Assignee: University of Maryland Baltimore County (University of Maryland)
• Original Assignee: University of Maryland Baltimore County (University of Maryland)
• Inventors: Mori, Yuriko, Meltzer, Stephen
• Application Number:
  US11/754,092
• Publication Number:
  US 20080081333A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2523/125 Bisulfite(s)
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/154 Methylation markers

Abstract

The present invention provides methods for identifying or assessing probabilities for having or developing an abnormal condition in subject and for the recurrence of the abnormal condition in the subject after receiving treatment. The method comprises determining the methylation status of at least the tachykinin-1 (TAC1) gene in the subject and comparing this methylation status to normal methylation status. Differences between the methylation status of the TAC1 gene is indicative of the subject developing an abnormal condition or for the development or recurrence of the abnormal conditions after receiving treatment.

Claims

1. A method for diagnosing the presence of an abnormal condition in a subject suspected of having an abnormal condition, said method comprising

a) determining a methylation status of at least one gene in the subject;

and

b) comparing the methylation status of said at least one gene in said subject to the normal methylation status of said at least one gene;

wherein a difference between the methylation status of said at least one gene in said subject and the normal methylation status of said at least one gene is indicative of the presence or absence or colon cancer in the subject, and wherein said at least one gene is tachykinin-1 (TAC1).

2. The method of claim 1, wherein the abnormal condition is colon cancer, esophageal cancer or gastric cancer.

3. The method of claim 2, further comprising determining the methylation status of the somatostatin gene (SST).

4. The method of claim 3, wherein said determining said methylation status comprises using an assay selected from the group consisting of Southern blotting, single nucleotide primer extension, methylation-specific polymerase chain reaction (MSP), restriction landmark genomic scanning for methylation (RLGS-M), CpG island microarray, SNUPE, and COBRA.

5. The method of claim 3, wherein the methylation status of a panel of genes is determined and compared to the normal methylation status of said panel of genes.

6. The method of claim 5, wherein said panel comprises three or more genes.

7. The method of claim 6, wherein said panel comprises at least 4 or 5 genes.

8. The method of claim 7, wherein said panel comprises at least 5 genes.

9. The method of claim 8, wherein said panel comprises TAC1, SST, nel-like type 1 (NELL1), A kinase [PRKA] anchor protein [gravin] 12 (AKAP12), caveolin, endoglin and T-lymphocyte maturation associated protein (MAL).

10. A method of monitoring the development of an abnormal condition in a subject, said method comprising

a) determining a methylation status of at least one gene in said subject at a first and second time point;

and

b) determining a difference between said methylation status at said first and second time points to assess a change of methylation status over time;

wherein said difference over time is indicative of a change in the subject'"'"'s probability of developing said abnormal condition, and wherein said at least one gene comprises tachykinin-1 (TAC1).

11. The method of claim 10, wherein the abnormal condition is colon cancer, esophageal cancer or gastric cancer.

12. The method of claim 11, further comprising determining the methylation status of the somatostatin gene (SST).

13. The method of claim 12, wherein said determining said methylation status comprises using an assay selected from the group consisting of Southern blotting, single nucleotide primer extension, methylation-specific polymerase chain reaction (MSP), restriction landmark genomic scanning for methylation (RLGS-M), CpG island microarray, SNUPE, and COBRA.

14. The method of claim 12, wherein the methylation status of a panel of genes is determined and compared to the normal methylation status of said panel of genes.

15. The method of claim 14, wherein said panel comprises three or more genes.

16. The method of claim 15, wherein said panel comprises at least 4 or 5 genes.

17. The method of claim 16, wherein said panel comprises at least 5 genes.

18. The method of claim 17, wherein said panel comprises TAC1, SST, nel-like type 1 (NELL1), A kinase [PRKA] anchor protein [gravin] 12 (AKAP12), caveolin, endoglin and T-lymphocyte maturation associated protein (MAL).

19. A method for assessing the probability of a subject having an abnormal condition, said method comprising

a) determining a methylation status of at least one gene in gross normal tissue of the subject;

and

b) comparing the methylation status of said at least one gene in said subject to the normal methylation status of said at least one gene;

wherein a difference between the methylation status of said at least one gene in said gross normal tissue of said subject and the normal methylation status of said at least one gene indicates that the subject has an altered probability of having said abnormal condition, wherein said at least one gene is tachykinin-1 (TAC1).